These results support the prevailing role of hepatic insulin sensitivity over that of other tissues in the pathogenesis of metabolic diseases, such as NAFLD, obesity, and T2DM, and highlight the importance of restoring insulin sensitivity–mediated liver metabolism through pharmacological and gene therapy. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.